Physician profile
David E Wexler
NPI 1386637254
$1,633.47
in general payments reported to CMS, 2019-2025
24 companies · $328 in 2025
The $328 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $183 · 2021: $230 · 2022: $329 · 2023: $154 · 2024: $100 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $300.08 | 2019-2025 | |
| Abbvie INC. | $210.00 | 2019-2025 | Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.20 | 2019-2021 | |
| Gilead Sciences, INC. | $123.45 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.66 | 2019-2022 | |
| Qol Medical, LLC | $77.25 | 2021-2024 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $72.90 | 2019-2022 | |
| Celgene Corporation | $55.37 | 2021-2022 | |
| Shionogi INC | $53.26 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $51.80 | 2024-2025 | Voquezna |
| Becton, Dickinson and Company | $44.77 | 2022 | |
| Intercept Pharmaceuticals, INC. | $42.69 | 2022 | |
| Redhill Biopharma INC. | $42.17 | 2022 | |
| Nestle Healthcare Nutrition INC. | $41.53 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $35.82 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35.44 | 2024-2025 | Omvoh |
| Amag Pharmaceuticals, INC. | $28.26 | 2019 | |
| Novo Nordisk INC | $20.17 | 2025 | Wegovy |
| Celltrion USA INC. | $18.94 | 2025 | Vegzelma |
| Boston Scientific Corporation | $18.93 | 2022 | |
| Ferring Pharmaceuticals INC. | $16.93 | 2024 | Rebyota |
| Olympus America INC. | $14.16 | 2021 | |
| Janssen Biotech, INC. | $13.89 | 2022 | |
| Ardelyx, INC. | $12.80 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wexler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.